Tagomics is a leader in precision medicine, with exciting applications in drug safety and oncology. The company’s proprietary platform enables unparalleled access to clinically relevant biomarkers from a single blood sample. Combined with advanced bioinformatic and machine-learning analyses, the platform delivers unique biological understanding, supports high-throughput disease profiling and enables earlier, more precise diagnosis.
Based in Cambridge, UK, Tagomics was launched in 2021 as a spin-out from the University of Birmingham to build upon research led by Professor Robert Neely, the company’s Chief Scientific Officer, and Dr Jack Kennefick, the company’s Chief Executive Officer. The company has since developed a suite of pioneering “omics” technologies, which seamlessly combine the company’s novel approach to epigenomics (studying chemical “switches” on the genome) with genomics (detecting mutations and other structural variants) and fragmentomics (the analysis of DNA fragmentation patterns in the blood). By integrating these methods and applying advanced data analysis and machine learning, Tagomics’ platform can provide a 360° understanding of human health and disease.
